FindTrial
Sign In

pegcrisantaspase

DRUG2 trials

Sponsors

Jazz Pharmaceuticals, M.D. Anderson Cancer Center

Conditions

Acute Lymphoblastic LeukemiaBlast Phase Chronic Myelogenous Leukemia, BCR-ABL1 PositiveLymphoblastic LymphomaRecurrent Acute Biphenotypic LeukemiaRecurrent Acute Lymphoblastic LeukemiaRecurrent Acute Myeloid LeukemiaRecurrent Chronic Myelogenous Leukemia, BCR-ABL1 PositiveRecurrent T-Cell Prolymphocytic Leukemia

Phase 1

Fludarabine, Cytarabine, and Pegcrisantaspase for the Treament of Relapsed or Refractory Leukemia
TerminatedNCT04526795
M.D. Anderson Cancer CenterBlast Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Recurrent Acute Biphenotypic Leukemia, Recurrent Acute Lymphoblastic Leukemia +8
Start: 2021-04-09End: 2024-11-15Updated: 2024-12-12

Phase 2

A Dose Confirmation and Pharmacokinetic Study of Pegcrisantaspase Administered as Intravenous (IV) Infusion in Children and Young Adults With Acute Lymphoblastic Leukemia (ALL) /Lymphoblastic Lymphoma (LBL). Following Hypersensitivity to Pegaspargase (Oncaspar)
TerminatedNCT02257684
Jazz PharmaceuticalsAcute Lymphoblastic Leukemia, Lymphoblastic Lymphoma
Start: 2014-09-30End: 2016-01-31Updated: 2017-04-04